Smith & Nephew SNATS (SNN) Stock Price, News & Analysis

Company Overview

Smith & Nephew plc is a global medical technology company headquartered in Watford, England. Founded in 1856 by pharmacist Thomas James Smith in Hull, the company has grown from a pharmacy business into a provider of surgical and wound-care products for healthcare professionals and patients.

The company operates through three principal areas: Orthopaedics, Sports Medicine, and Advanced Wound Management. Its products include joint-replacement systems, trauma and extremity devices, arthroscopy equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products used to support healing and tissue recovery.

Smith & Nephew serves hospitals, clinics, surgeons, and patients in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific, and other international regions. Its ordinary shares are listed in the United Kingdom, and its American depositary shares trade on the New York Stock Exchange under the symbol SNN.

Key Stats

• Today's Range: $27.57 to $27.97
• 50-Day Range: $26.45 to $30.48
• 52-Week Range: $26.12 to $37.51
• Volume: 781,243 shs
• Average Volume: 1.27 million shs
• Market Capitalization: $11.71 billion
• P/E Ratio: N/A
• Dividend Yield: 2.12%
• Price Target: $31.91
• Consensus Rating: Hold

Smith & Nephew SNATS Stock Analysis - MarketRank™

Smith & Nephew SNATS scored higher than 54% of companies evaluated by MarketBeat, and ranked 453rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Smith & Nephew SNATS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 10 hold ratings, and 1 sell rating.

Upside Potential

Smith & Nephew SNATS has a consensus price target of $31.91, representing about 14.5% upside from its current price of $27.87.

Amount of Analyst Coverage

Smith & Nephew SNATS has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 5.48%

Earnings Growth

Earnings for Smith & Nephew SNATS are expected to grow by 5.48% in the coming year, from $2.19 to $2.31 per share.

Price to Earnings Growth Ratio

Smith & Nephew SNATS has a PEG Ratio of 1.51. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Smith & Nephew SNATS has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.12% of the float of Smith & Nephew SNATS has been sold short.

Short Interest Ratio / Days to Cover

Smith & Nephew SNATS has a short interest ratio ("days to cover") of 3.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Smith & Nephew SNATS has recently decreased by 3.52%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Smith & Nephew SNATS pays a meaningful dividend of 2.18%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Smith & Nephew SNATS does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 25.54% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Smith & Nephew SNATS has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Smith & Nephew SNATS this week, compared to 1 article on an average week.

Search Interest

1 people have searched for SNN on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Smith & Nephew SNATS to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Smith & Nephew SNATS is held by insiders.

Percentage Held by Institutions

25.64% of the stock of Smith & Nephew SNATS is held by institutions.

Company Calendar

• Last Earnings: 11/17/2014
• Record date for 11/6 Dividend: 10/02/2026
• Ex-Dividend for 11/6 Dividend: 10/02/2026
• Today: 10/13/2026
• Dividend Payable: 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:SNN
• CIK: 845982
• Web: www.smith-nephew.com
• Phone: 441923477100
• Fax: 44-20-7930-3353
• Employees: 16,988
• Year Founded: 1856

Price Target and Rating

• Average Price Target for Smith & Nephew SNATS: $31.91
• High Price Target: $33.88
• Low Price Target: $30.00
• Potential Upside/Downside: +14.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 12.73
• P/E Growth: 1.51
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 2.14
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $6.16 billion
• Price / Sales: 1.90
• Cash Flow: $3.51 per share
• Price / Cash Flow: 7.94
• Book Value: $12.45 per share
• Price / Book: 2.24

Miscellaneous

• Outstanding Shares: 419,930,000
• Free Float: 415,730,000
• Market Cap: $11.70 billion
• Optionable: Optionable
• Beta: 0.53